Integral Health Asset Management LLC Has $22.86 Million Stock Holdings in RadNet, Inc. $RDNT

Integral Health Asset Management LLC decreased its position in shares of RadNet, Inc. (NASDAQ:RDNT) by 25.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 300,000 shares of the medical research company’s stock after selling 100,000 shares during the quarter. RadNet comprises approximately 1.5% of Integral Health Asset Management LLC’s investment portfolio, making the stock its 16th biggest holding. Integral Health Asset Management LLC’s holdings in RadNet were worth $22,863,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the company. AQR Capital Management LLC grew its holdings in shares of RadNet by 5.4% in the 1st quarter. AQR Capital Management LLC now owns 6,846 shares of the medical research company’s stock valued at $340,000 after buying an additional 350 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in RadNet by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 39,341 shares of the medical research company’s stock worth $1,956,000 after buying an additional 1,699 shares during the period. Jones Financial Companies Lllp raised its stake in RadNet by 563.4% during the 1st quarter. Jones Financial Companies Lllp now owns 1,705 shares of the medical research company’s stock worth $85,000 after buying an additional 1,448 shares during the period. United Services Automobile Association bought a new position in RadNet during the first quarter worth about $216,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in RadNet by 2.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 440,543 shares of the medical research company’s stock worth $21,904,000 after acquiring an additional 8,762 shares in the last quarter. Institutional investors and hedge funds own 77.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the company. Weiss Ratings restated a “sell (d-)” rating on shares of RadNet in a report on Monday, December 29th. KeyCorp upgraded RadNet to a “strong-buy” rating in a report on Friday, January 9th. The Goldman Sachs Group upgraded RadNet to a “buy” rating in a research report on Tuesday, December 16th. B. Riley Financial increased their target price on RadNet from $71.00 to $87.00 and gave the stock a “buy” rating in a research note on Monday, December 1st. Finally, Jefferies Financial Group restated a “buy” rating and set a $91.00 target price on shares of RadNet in a report on Tuesday, March 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $90.43.

RadNet Stock Performance

Shares of RDNT opened at $62.09 on Friday. The stock has a market capitalization of $4.82 billion, a price-to-earnings ratio of -248.36 and a beta of 1.49. RadNet, Inc. has a 12 month low of $45.00 and a 12 month high of $85.84. The firm has a fifty day simple moving average of $70.23 and a 200 day simple moving average of $74.06. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.79.

RadNet (NASDAQ:RDNT) last issued its quarterly earnings results on Monday, March 2nd. The medical research company reported $0.23 EPS for the quarter, topping the consensus estimate of $0.19 by $0.04. RadNet had a negative net margin of 0.91% and a positive return on equity of 2.52%. The firm had revenue of $547.71 million for the quarter, compared to analysts’ expectations of $515.67 million. During the same period in the previous year, the firm posted $0.22 EPS. The company’s revenue for the quarter was up 14.8% on a year-over-year basis. Research analysts forecast that RadNet, Inc. will post 0.56 EPS for the current fiscal year.

About RadNet

RadNet, Inc is a leading independent provider of outpatient diagnostic imaging services in the United States. Through a nationwide network of fixed-site imaging centers and affiliated joint-venture locations, the company delivers a comprehensive suite of radiology services including MRI, CT, PET/CT, ultrasound, X-ray, mammography, bone densitometry, nuclear medicine and interventional radiology procedures. RadNet also offers teleradiology and imaging management solutions to physician practices, hospitals and healthcare systems.

Founded in 1981 and headquartered in Los Angeles, RadNet has expanded its footprint organically and through strategic acquisitions.